Summary & Overview
HCPCS S2120: LDL Apheresis via Heparin-Induced Extracorporeal Precipitation
HCPCS Level II code S2120 designates low density lipoprotein (LDL) apheresis performed by heparin-induced extracorporeal LDL precipitation. This specialized therapeutic procedure is used to acutely lower LDL cholesterol levels in patients with refractory hypercholesterolemia or specific lipid disorders where pharmacologic therapy is insufficient. The code matters nationally because it represents a high-cost, resource-intensive service with implications for coverage policy, care coordination, and site-of-service billing.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find an explanation of the clinical service represented by S2120, typical settings where the procedure is delivered, and which payers commonly cover or manage access to the service. The publication also summarizes benchmarks and policy-relevant considerations, including utilization drivers, documentation expectations, and potential authorization requirements. Where payer-specific details are not provided in the input, the report notes that those data are not available.
This summary is intended for payers, billing professionals, and clinical managers seeking a concise reference to the clinical and administrative context of HCPCS Level II code S2120 and what to expect when this apheresis procedure is billed in the outpatient environment.
Billing Code Overview
HCPCS Level II code S2120 describes low density lipoprotein (LDL) apheresis using heparin-induced extracorporeal LDL precipitation. This service is a form of therapeutic apheresis that removes LDL cholesterol from the bloodstream by precipitating lipoproteins extracorporeally using heparin, and then returning treated blood components to the patient.
Service type: Therapeutic LDL apheresis procedure
Typical site of service: Hospital outpatient department or specialized apheresis center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with refractory heterozygous or homozygous familial hypercholesterolemia or severe, treatment‑resistant hypercholesterolemia who has persistently elevated low‑density lipoprotein cholesterol (LDL‑C) despite maximally tolerated lipid‑lowering therapy. The patient is referred to an apheresis center by a lipidologist, cardiologist, or primary care provider for LDL apheresis using heparin‑induced extracorporeal LDL precipitation (S2120).
The clinical workflow begins with pre‑procedure evaluation including review of recent lipid panels, medication list, vascular access assessment, and coagulation studies. Informed consent is obtained. Vascular access (temporary peripheral venous or tunneled central venous catheter or arteriovenous fistula) is secured. The apheresis team prepares extracorporeal circuit and heparin reagents for heparin‑induced LDL precipitation. During the procedure, the patient is monitored for hemodynamic stability, anticoagulation effect, and potential adverse events (bleeding, hypotension, allergic reaction). Post‑procedure, lipid panel and hemodynamic monitoring are performed, access site care is provided, and follow‑up lipid management is coordinated with the referring specialist. Typical treatment is recurring at regular intervals (often every 1–2 weeks) for patients requiring chronic therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |